Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide

Manufacturer
Ingenus Pharmaceuticals, LLC
Effective date
2023-01-12
Label type
Human Prescription Drug Label
Version
2
Source
full-release
Hydrated at
2026-05-31 20:46:26

Label at a glance#

ProductPhenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide
Active ingredientPHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE
Label structure14 sections

Dosage and administration

The dosage of Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse effects.  Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir. Adults: One or two teaspoonfuls of elixir three or four times a day according to conditions and severity o...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir - Grape
Each 5 mL (teaspoonful) of elixir (alcohol not more than 23.8%) contains:
 Phenobarbital, USP................................. 16.2 mg
 Hyoscyamine Sulfate, USP................ 0.1037 mg
 Atropine Sulfate, USP......................... 0.0194 mg
 Scopolamine Hydrobromide, USP.... 0.0065 mg

Inactive Ingredients
Purified Water, Glycerin, Sorbitol, Ethyl Alcohol, Sucrose, Saccharin Sodium, Artificial and Natural Grape Flavor, FD&C Red #3, and FD&C Blue #1.

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir – Mint
Each 5 mL (teaspoonful) of elixir (alcohol not more than 23.8%) contains:
 Phenobarbital, USP................................. 16.2 mg
 Hyoscyamine Sulfate, USP................ 0.1037 mg
 Atropine Sulfate, USP......................... 0.0194 mg
 Scopolamine Hydrobromide, USP.... 0.0065 mg

Inactive Ingredients
Purified Water, Glycerin, Sorbitol, Ethyl Alcohol, Sucrose, Saccharin Sodium, Natural Mint Flavor, FD&C Yellow #5, and FD&C Blue #1.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.

INDICATIONS AND USAGE
Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: “Possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

May also be useful as adjunctive therapy in the treatment of duodenal ulcer.

Final classification of the less-than-effective indications requires further investigation.

IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. 

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

  • glaucoma; 
  • obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); 
  • obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); 
  • paralytic ileus, intestinal atony of the elderly or debilitated patient;
  • unstable cardiovascular status in acute hemorrhage; 
  • severe ulcerative colitis especially if complicated by toxic megacolon; 
  • myasthenia gravis; 
  • hiatal hernia associated with reflux esophagitis; 
  • in patients with known hypersensitivity to any of the ingredients.

Phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.

WARNINGS

WARNINGS SECTION

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir can cause fetal harm when administered to a pregnant woman. Animal reproduction studies have not been conducted with Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and heatstroke due to decreased sweating).

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful.

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.

Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs.

Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Use with caution in patients with:

  • autonomic neuropathy
  • hepatic or renal disease
  • hyperthyroidism
  • coronary heart disease
  • congestive heart failure
  • cardiac arrhythmias
  • tachycardia
  • hypertension

Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of gastric ulcer.

Do not rely on the use of the drug in the presence of complication of biliary tract disease.

Theoretically, with overdosage, a curare-like action may occur.

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir – Mint contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.

Drug Interactions

DRUG INTERACTIONS SECTION

Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy

PREGNANCY SECTION

Animal reproduction studies have not been conducted with Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks (see WARNINGS).

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir is administered to a nursing woman.

Geriatric Use

GERIATRIC USE SECTION

Elderly patients may react with symptoms of excitement, agitation, drowsiness, and other untoward manifestations to even small doses of the drug.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Adverse reactions may include xerostomia; urinary hesitancy and retention; blurred vision; tachycardia; palpitation; mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria, and other dermal manifestations; and decreased sweating.

Acquired hypersensitivity to barbiturates consists chiefly in allergic reactions that occur especially in persons who tend to have asthma, urticaria, angioedema, and similar conditions. Hypersensitivity reactions in this category include localized swelling, particularly of the eyelids, cheeks, or lips, and erythematous dermatitis. Rarely, exfoliative dermatitis (e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis) may be caused by phenobarbital and can prove fatal. The skin eruption may be associated with fever, delirium, and marked degenerative changes in the liver and other parenchymatous organs. In a few cases, megaloblastic anemia has been associated with the chronic use of phenobarbital.

Phenobarbital may produce excitement in some patients, rather than a sedative effect.

To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

Abuse

ABUSE SECTION

Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see WARNINGS).

Dependence

DEPENDENCE SECTION

In patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

OVERDOSAGE

OVERDOSAGE SECTION

The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot and dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. Treatment should consist of gastric lavage, emetics, and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride should be used.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dosage of Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse effects. 

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir. Adults: One or two teaspoonfuls of elixir three or four times a day according to conditions and severity of symptoms.

Pediatric patients: may be dosed every 4 to 6 hours. Use a pediatric dosing device or oral syringe to measure the dose.

                                      Starting Dosage

Body weight                 Every 4 hours                 Every 6 hours
10 lb. (4.5 kg)                          0.5 mL                           0.75 mL
20 lb. (9.1 kg)                          1 mL                              1.5 mL
30 lb. (13.6 kg)                        1.5 mL                           2 mL
50 lb. (22.7 kg)                        2.5 mL                           3.75 mL
75 lb. (34 kg)                           3.75 mL                         5 mL
100 lb. (45.4 kg)                      5 mL                              7.5 mL

HOW SUPPLIED

HOW SUPPLIED SECTION

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir - Grape is a purple colored, grape flavored liquid.

  • 4 fl oz (118 mL) bottles- NDC 50742-666-04.
  • 1 Pint (473 mL) bottles- NDC 50742-666-16.

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir - Mint is a green colored, mint flavored liquid.

  • 4 fl oz (118 mL) bottles- NDC 50742-665-04.
  • 1 Pint (473 mL) bottles- NDC 50742-665-16.

Avoid Freezing

Store Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide Elixir at 20° - 25°C (68° - 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

DEA EXEMPT PRODUCT

Manufactured for: 
Ingenus Pharmaceuticals, LLC
Orlando, FL 32839-6408

Revised: 05/2021 
LF-122298-01
MPL-100

logologo

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 4 OZ GRAPE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 50742-666-04
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide
Elixir Grape Flavored
Each 5 mL (1 teaspoonful) contains:
Phenobarbital, USP........................ 16.2 mg
Hyoscyamine Sulfate, USP........... 0.1037 mg
Atropine Sulfate, USP................... 0.0194 mg
Scopolamine Hydrobromide, USP....0.0065 mg

Alcohol not more than 23.8%

DO NOT USE IF TAMPER-EVIDENT SEAL UNDER CAP IS BROKEN OR MISSING

Rx Only

4 FL OZ

Ingenus


bottle-label-4oz-grape
bottle-label-4oz-grape

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 1 PINT GRAPE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 50742-666-16

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide
Elixir Grape Flavored
Each 5 mL (1 teaspoonful) contains:
Phenobarbital, USP........................ 16.2 mg
Hyoscyamine Sulfate, USP........... 0.1037 mg
Atropine Sulfate, USP................... 0.0194 mg
Scopolamine Hydrobromide, USP....0.0065 mg
Alcohol not more than 23.8%
DO NOT USE IF TAMPER-EVIDENT SEAL UNDER CAP IS BROKEN OR MISSING

Bulk Container-Not For Household Use

Rx Only

1 Pint

Ingenus


bottle-label-16oz-grapebottle-label-16oz-grape

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 4 OZ MINT

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 50742-665-04
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide
Elixir Mint Flavored
Each 5 mL (1 teaspoonful) contains:
Phenobarbital, USP........................ 16.2 mg
Hyoscyamine Sulfate, USP........... 0.1037 mg
Atropine Sulfate, USP................... 0.0194 mg
Scopolamine Hydrobromide, USP....0.0065 mg

Alcohol not more than 23.8%
DO NOT USE IF TAMPER-EVIDENT SEAL UNDER CAP IS BROKEN OR MISSING

Rx Only

4 FL OZ
Ingenus

bottle-label-4oz-mintbottle-label-4oz-mint

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 1 PINT MINT

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 50742-665-16

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide
Elixir Mint Flavored
Each 5 mL (1 teaspoonful) contains:
Phenobarbital, USP........................ 16.2 mg
Hyoscyamine Sulfate, USP........... 0.1037 mg
Atropine Sulfate, USP................... 0.0194 mg
Scopolamine Hydrobromide, USP.....0.0065 mg

Alcohol not more than 23.8%

contains color additives including FD&C Yellow No. 5 (tartrazine)
DO NOT USE IF TAMPER-EVIDENT SEAL UNDER CAP IS BROKEN OR MISSING

Bulk Container - Not For Household Use

Rx Only

1 Pint
Ingenus

bottle-label-16oz-mintbottle-label-16oz-mint


DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1046787PHENobarbital 16.2 MG / hyoscyamine sulfate 0.1037 MG / atropine sulfate 0.0194 MG / scopolamine HBr 0.0065 MG in 5 mL Oral SolutionPSN2
1046787atropine sulfate 0.00388 MG/ML / hyoscyamine sulfate 0.0207 MG/ML / phenobarbital 3.24 MG/ML / scopolamine hydrobromide 0.0013 MG/ML Oral SolutionSCD2
1046787atropine sulfate 0.0194 MG / hyoscyamine sulfate 0.1037 MG / phenobarbital 16.2 MG / scopolamine hydrobromide 0.0065 MG per 5 ML Oral SolutionSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ATROPINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
SCOPOLAMINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6c78bd43-efb4-4aeb-b7d8-eff1532f7822Product name420250801
41231c1e-8789-4da7-ac52-77fa90a85bf5Product name220250304
fe8ea78e-e1a4-44bf-a6b2-42eed76976bbProduct name520250218
e77ab9a2-80cf-4832-bff0-469bbc7cbcd0Product name220250214
5f84b7a7-523a-f042-dffb-1dadcd9b2407Product name420240110
e3e67a66-d325-4d80-8f9d-059e736d7b00Product name120230912
0cbc6fb2-78c0-4b88-98f0-a4cc76ff95caProduct name120230719
04cd5dc0-102f-46cb-8dbc-ca38dd2628d0Product name320230317
dfd25202-b8d2-4628-9213-f3e0f9eafce5Product name420210513
4199bf9b-4718-828a-6dd6-ac2fbbd61687Product name120140508
4edd8af5-cea7-ae42-8023-e91c5335db1dProduct name120140508
d3908afb-7784-440f-c406-88294732d36aProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50742-665-04Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide118 mL in 1 BOTTLEELIXIR1182
50742-665-16Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide473 mL in 1 BOTTLEELIXIR4732
50742-666-04Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide118 mL in 1 BOTTLEELIXIR1182
50742-666-16Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide473 mL in 1 BOTTLEELIXIR4732

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50742-665PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE ELIXIR [INGENUS PHARMACEUTICALS, LLC]2Current NDC, Legacy NDC, 2 package rows20230120_33bf2df5-bc53-4d57-a9e7-41f3fc0a03f0.zip
50742-666PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE ELIXIR [INGENUS PHARMACEUTICALS, LLC]2Current NDC, Legacy NDC, 2 package rows20230120_33bf2df5-bc53-4d57-a9e7-41f3fc0a03f0.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50742-666-04ML - Milliliter50742-66601904ebc-8b1a-41cf-b130-86e61043c53412022-01-06
50742-666-16ML - Milliliter50742-666f538a322-3376-4b91-985b-ec10b6d760aa12022-01-06
50742-665-04ML - Milliliter50742-665cf7e0398-c574-4878-9756-e7f0f525000212022-01-06
50742-665-16ML - Milliliter50742-665b53137f7-405e-4e5b-bdde-ec13ff03462e12022-01-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50742-66650742-666-04, 50742-666-16
50742-66550742-665-04, 50742-665-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 24 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine HydrobromidePHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDEIngenus Pharmaceuticals, LLC33bf2df5-bc53-4d57-a9e7-41f3fc0a03f02023-01-12Warnings, Adverse reactionsExact identifier
ndc (package): 50742-666-16
ndc (package): 50742-665-16
ndc (package): 50742-666-04
ndc (package): 50742-665-04
ndc (product): 50742-666
ndc (product): 50742-665
ndc11 (package): 50742066604
ndc11 (package): 50742066516
ndc11 (package): 50742066504
ndc11 (package): 50742066616
spl id: 5e9a2654-23e8-43de-a8fa-d981d7f13e40
spl set id: 33bf2df5-bc53-4d57-a9e7-41f3fc0a03f0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.